中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(6): 1375-1382

Value of quantitative imaging parameters combined with serum tumor markers in prognostic evaluation after pancreatic ductal adenocarcinoma surgery

DOI: 10.12449/JCH260620

  • Department of Hepatobiliary Surgery，Hebei Medical University Fourth Hospital，Shijiazhuang 050000，China

Research funding:

Medical Science Research Project of Hebei Province (20260565)

More Information
  • Corresponding author: YANG Baoming， gdybm1983@163.com （ORCID： 0009-0006-9116-8547）
  • Received Date: 2026-01-01
  • Accepted Date: 2026-02-26
  • Published Date: 2026-06-25
    Abstract
  •   Objective  To investigate the application value of a predictive model constructed based on quantitative imaging parameters and serum tumor markers in predicting the postoperative prognosis of patients with pancreatic ductal adenocarcinoma （PDAC）.  Methods  A retrospective study was conducted among 146 patients with PDAC who underwent radical resection in Hebei Medical University Fourth Hospital from April 2020 to March 2023， and the patients were divided into a training set with 102 patients and a validation set of 44 patients at a ratio of 7∶3 using the completely randomized method. All patients underwent enhanced computed tomography （CT） and multi-parametric magnetic resonance imaging scans， and CT values in the arterial phase， the venous phase， and the delayed phase were recorded， as well as apparent diffusion coefficient （ADC） at b = 800 s/mm2 and signal intensity （SI） of T2 weighted imaging. The serum levels of carbohydrate antigen 19-9 （CA19-9） and carcinoembryonic antigen （CEA） were also measured. The independent-samples t test was used for comparison of continuous data between groups， and the chi-square test was used for comparison of categorical data between groups. Kaplan-Meier survival curves were plotted for survival analysis； the univariate and multivariate Logistic regression analysis was used to investigate the association of clinical and imaging indicators with prognosis； the least absolute shrinkage and selection operator （LASSO）-Cox regression model was used to identify the important influencing factors for prognosis， and a prognostic prediction model was constructed. The receiver operating characteristic （ROC） curve was used to analyze the predictive value of the model in predicting prognosis in both the training set and the validation set.  Results  The Kaplan-Meier survival curve analysis showed a median survival time of 33.00 months in the training set and 32.00 months in the validation set， with no significant difference between the training set and the validation set （P>0.05）. The univariate analysis showed that patient age， degree of tumor differentiation， lymph node metastasis， tumor stage， vascular invasion， CA19-9， CEA， ADC value， and SI value were significantly associated with the survival prognosis of patients （χ²=5.906， 13.116， 12.807， 17.277， 14.611， 7.275， 14.339， 9.506， and 13.137， all P<0.05）. The LASSO-Cox multivariate regression analysis showed that six factors were incorporated into the regression model， i.e.， tumor stage （HR=8.934， 95%CI： 3.215 — 21.562， P<0.001）， lymph node metastasis （HR=2.971， 95%CI： 1.298 — 5.647， P=0.002）， CA19-9 （HR=3.948， 95%CI： 1.758 — 8.994， P<0.001）， CEA （HR=1.965， 95%CI： 1.083 — 3.664， P=0.039）， ADC value （HR=2.873， 95%CI： 1.307 — 6.037， P=0.003）， and SI value （HR=3.107， 95%CI： 1.264 — 7.339， P=0.001）. The nomogram model constructed based on these factors had an area under the ROC curve of 0.845 （95%CI： 0.774 — 0.915） in the training set and 0.919 （95%CI： 0.870 — 0.967） in the validation set.  Conclusion  The combined model of quantitative imaging parameters and serum tumor markers constructed based on LASSO-Cox regression can effectively predict the postoperative prognosis of PDAC patients， thereby helping to identify high-risk patients and guide decision-making for adjuvant therapy.

     

    • FullText(HTML)
  • loading
    • References(27)
  • [1]
    WANG T, YE L, LUO JG, et al. Expression and significance of miR-510 in pancreatic ductal adenocarcinoma[J]. China J Gen Surg, 2025, 34( 2): 390- 396. DOI: 10.7659/j.issn.1005-6947.240592.

    王涛, 叶林, 罗纪光, 等. miR-510在胰腺导管腺癌中的表达及意义[J]. 中国普通外科杂志, 2025, 34( 2): 390- 396. DOI: 10.7659/j.issn.1005-6947.240592.
    [2]
    GROSSBERG AJ, CHU LC, DEIG CR, et al. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma[J]. CA Cancer J Clin, 2020, 70( 5): 375- 403. DOI: 10.3322/caac.21626.
    [3]
    SCHIMA W, BÖHM G, RÖSCH CS, et al. Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation[J]. Cancer Imaging, 2020, 20( 1): 52. DOI: 10.1186/s40644-020-00324-z.
    [4]
    LIU ZH, LONG D, WANG Q, et al. MicroRNA-324-5p targeting transmembrane and coiled-coil domain family 1 regulates the proliferation of pancreatic ductal adenocarcinoma cells[J]. Chin J Exp Surg, 2025, 42( 1): 29- 32. DOI: 10.3760/cma.j.cn421213-20240808-00023.

    刘宗昊, 龙迪, 王琦, 等. 微小RNA-324-5p靶向卷曲结构域家族1调控胰腺导管腺癌细胞增殖的实验研究[J]. 中华实验外科杂志, 2025, 42( 1): 29- 32. DOI: 10.3760/cma.j.cn421213-20240808-00023.
    [5]
    LU PY, ZHAI J, LI YC, et al. Prognostic value of preoperative quantitative CT analysis of body components in patients with radical resection of pancreatic ductal adenocarcinoma[J]. Radiol Pract, 2025, 40( 2): 243- 247. DOI: 10.13609/j.cnki.1000-0313.2025.02.016.

    鹿佩瑶, 翟建, 李云成, 等. 术前定量CT分析身体组分对根治性切除术胰腺导管腺癌患者预后的预测价值[J]. 放射学实践, 2025, 40( 2): 243- 247. DOI: 10.13609/j.cnki.1000-0313.2025.02.016.
    [6]
    LI RT, ZHAO HF, WANG XD, et al. Research progress of artificial intelligence and radiomics in preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma[J]. Chin J Magn Reson Imag, 2025, 16( 3): 211- 215. DOI: 10.12015/issn.1674-8034.2025.03.036.

    李锐彤, 赵海峰, 王晓东, 等. 人工智能及影像组学在术前预测胰腺导管腺癌淋巴结转移中的研究进展[J]. 磁共振成像, 2025, 16( 3): 211- 215. DOI: 10.12015/issn.1674-8034.2025.03.036.
    [7]
    TAO XF, XIANG H, PAN Y, et al. Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence[J]. Pharmacol Res, 2021, 168: 105595. DOI: 10.1016/j.phrs.2021.105595.
    [8]
    FAN WJ, DENG XQ, ZHENG LC, et al. Clinical value of ultrasound and contrast enhanced ultrasound in the differential diagnosis of pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma[J]. J China Med Univ, 2025, 54( 4): 359- 363. DOI: 10.12007/j.issn.0258-4646.2025.04.013.

    樊维娟, 邓小倩, 郑立春, 等. 超声及超声造影在鉴别胰腺神经内分泌瘤与胰腺导管腺癌中的临床价值[J]. 中国医科大学学报, 2025, 54( 4): 359- 363. DOI: 10.12007/j.issn.0258-4646.2025.04.013.
    [9]
    XIE D, LIANG HW, ZHOU Y, et al. Value of dual-energy CT parameters in evaluating the pathological grade of pancreatic ductal adenocarcinoma[J]. Chin J Endocr Surg, 2025, 19( 2): 266- 270. DOI: 10.3760/cma.j.cn.115807-20231030-00126.

    谢丹, 梁洪伟, 周旸, 等. 双能量CT参数对胰腺导管腺癌病理分级的评估价值[J]. 中华内分泌外科杂志(中英文), 2025, 19( 2): 266- 270. DOI: 10.3760/cma.j.cn.115807-20231030-00126.
    [10]
    TONG T, GU JH, XU D, et al. Deep learning radiomics based on contrast-enhanced ultrasound images for assisted diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis[J]. BMC Med, 2022, 20( 1): 74. DOI: 10.1186/s12916-022-02258-8.
    [11]
    PAPADAKOS SP, DEDES N, GKOLEMI N, et al. The EPH/ephrin system in pancreatic ductal adenocarcinoma(PDAC): From pathogenesis to treatment[J]. Int J Mol Sci, 2023, 24( 3): 3015. DOI: 10.3390/ijms24033015.
    [12]
    DU YS, GAO HY, LIU DX, et al. Predictive value of CT based radiomics model for the prognosis of patients with pancreatic ductal adenocarcinoma[J]. Chin J Dig Surg, 2025, 24( 8): 1067- 1074. DOI: 10.3760/cma.j.cn115610-20250801-00506.

    杜岳姗, 高华钰, 刘丁瑕, 等. CT检查影像组学模型对胰腺导管腺癌预后的预测价值[J]. 中华消化外科杂志, 2025, 24( 8): 1067- 1074. DOI: 10.3760/cma.j.cn115610-20250801-00506.
    [13]
    ZENG LL, LI SS, YUE PF, et al. The value of clinical characteristics and hematological parameters for prognostic assessment of pancreatic cancer patients undergoing radical resection[J]. J Sichuan Univ Med Sci, 2024, 55( 3): 708- 716. DOI: 10.12182/20240560604.

    曾莲丽, 李双双, 岳鹏飞, 等. 一般临床特征与血液学参数在胰腺导管腺癌根治性切除术患者中的预后价值研究[J]. 四川大学学报(医学版), 2024, 55( 3): 708- 716. DOI: 10.12182/20240560604.
    [14]
    ZHAO LH, HOU WJ, ZHAO J, et al. Application of qualitative and quantitative analysis of contrast-enhanced ultrasound in the differential diagnosis of pancreatic ductal adenocarcinoma and non-pancreatic ductal adenocarcinoma[J]. Chin J Ultrason, 2024, 33( 10): 855- 861. DOI: 10.3760/cma.j.cn131148-20240407-00214.

    赵利辉, 侯文静, 赵静, 等. 超声造影定性及定量分析在胰腺导管腺癌与非导管腺癌鉴别诊断中的应用价值[J]. 中华超声影像学杂志, 2024, 33( 10): 855- 861. DOI: 10.3760/cma.j.cn131148-20240407-00214.
    [15]
    WANG HZ, YANG X, CHEN XY, et al. The role of KRT6A in regulating the biological behavior of pancreatic ductal adenocarcinoma PANC1 cells and its role as a target for diagnosis and prognosis[J]. Chin J Cancer Biother, 2024, 31( 5): 462- 468. DOI: 10.3872/j.issn.1007-385x.2024.05.005.

    王浩泽, 杨轩, 陈昕苑, 等. KRT6A调控胰腺导管腺癌细胞生物学行为的作用及作为诊断与预后判断靶标的研究[J]. 中国肿瘤生物治疗杂志, 2024, 31( 5): 462- 468. DOI: 10.3872/j.issn.1007-385x.2024.05.005.
    [16]
    BARARIA A, DEY S, GULATI S, et al. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions[J]. Hepatobiliary Pancreat Dis Int, 2020, 19( 3): 205- 217. DOI: 10.1016/j.hbpd.2020.03.010.
    [17]
    LIU S, XIE C, LIU YH. Value of a nomogram model in early recurrence of pancreatic ductal adenocarcinoma after laparoscopic pancreaticoduodenectomy[J]. J Clin Hepatol, 2024, 40( 1): 138- 146. DOI: 10.12449/JCH240123.

    刘舜, 谢诚, 刘亚辉. 胰腺导管腺癌行腹腔镜下胰十二指肠切除术后早期复发的列线图模型及其预测价值分析[J]. 临床肝胆病杂志, 2024, 40( 1): 138- 146. DOI: 10.12449/JCH240123.
    [18]
    XU YW, WANG YF, HÖTI N, et al. The next"sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection[J]. Mass Spectrom Rev, 2023, 42( 2): 822- 843. DOI: 10.1002/mas.21748.
    [19]
    LIN GH, CHEN WY, XU CR, et al. Application value of dual-energy CT multi-parameter imaging in predicting the pathological grade of pancreatic ductal adenocarcinoma[J]. Chin J Dig Surg, 2025, 24( 1): 127- 136. DOI: 10.3760/cma.j.cn115610-20241213-00554.

    林桂涵, 陈炜越, 许彩如, 等. 双能量CT检查多参数成像预测胰腺导管腺癌病理学分级的应用价值[J]. 中华消化外科杂志, 2025, 24( 1): 127- 136. DOI: 10.3760/cma.j.cn115610-20241213-00554.
    [20]
    WANG J, LIAO JX, QIU Y, et al. Construction of a prognostic model for pancreatic ductal adenocarcinoma based on m6A-and m5C-related lncRNAs and its relationship with the immune microenvironment[J]. China J Gen Surg, 2025, 34( 3): 475- 484. DOI: 10.7659/j.issn.1005-6947.240563.

    王婕, 廖俊熙, 邱熠, 等. 基于m6A和m5C相关lncRNA的胰腺导管腺癌预后模型及其与免疫微环境的关系[J]. 中国普通外科杂志, 2025, 34( 3): 475- 484. DOI: 10.7659/j.issn.1005-6947.240563.
    [21]
    DU JL, GU JC, LI J. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels[J]. Biosci Rep, 2020, 40( 7): BSR20200401. DOI: 10.1042/BSR20200401.
    [22]
    CHEN G, SONG GX, HAN X, et al. Expression of Claudin18.2 in pancreatic ductal adenocarcinoma and its clinical pathological significance[J]. J Clin Pathol Res, 2024, 44( 10): 1352- 1358. DOI: 10.11817/j.issn.2095-6959.2024.240763.

    陈刚, 宋国新, 韩雪, 等. 胰腺导管腺癌中Claudin18.2的表达及其临床病理意义[J]. 临床与病理杂志, 2024, 44( 10): 1352- 1358. DOI: 10.11817/j.issn.2095-6959.2024.240763.
    [23]
    HASHIMOTO D, SATOI S, FUJII T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology(IAP)& the Japan Pancreas Society(JPS) 2022 in Kyoto[J]. Pancreatology, 2023, 23( 6): 682- 688. DOI: 10.1016/j.pan.2023.07.005.
    [24]
    ZHANG R, TIAN CJ, ZHANG X. Diagnostic value of contrast-enhanced computed tomography for mass-forming pancreatitis and pancreatic ductal adenocarcinoma[J]. Chin J Surg Integr Tradit West Med, 2024, 30( 5): 711- 715. DOI: 10.3969/j.issn.1007-6948.2024.05.021.

    张蕊, 田春江, 张翔. 增强CT对肿块型胰腺炎与胰腺导管腺癌的诊断价值研究[J]. 中国中西医结合外科杂志, 2024, 30( 5): 711- 715. DOI: 10.3969/j.issn.1007-6948.2024.05.021.
    [25]
    KONG M, XIA HC, ZHU FL. Imaging differential diagnosis of autoimmune pancreatitis from pancreatic ductal adenocarcinoma[J]. J Pract Radiol, 2023, 39( 1): 75- 78. DOI: 10.3969/j.issn.1002-1671.2023.01.019.

    孔梅, 夏好成, 朱付立. 自身免疫性胰腺炎和胰腺导管腺癌影像学鉴别[J]. 实用放射学杂志, 2023, 39( 1): 75- 78. DOI: 10.3969/j.issn.1002-1671.2023.01.019.
    [26]
    SAKURAI Y, YOKOYAMA K, KANNO A, et al. Pancreatic ductal adenocarcinoma with autoimmune pancreatitis: A case report and literature review[J]. Intern Med, 2025, 64( 10): 1525- 1533. DOI: 10.2169/internalmedicine.4361-24.
    [27]
    ZHUANG Y, CHEN J, LI JY, et al. Value of multiparameter MRI radiomics model in predicting the pathological diferentiation of pancreatic ductal adenocarcinoma[J]. J Clin Radiol, 2023, 42( 11): 1768- 1773. DOI: 10.13437/j.cnki.jcr.2023.11.015.

    庄雨, 陈杰, 李静燕, 等. 多参数MRI影像组学模型预测胰腺导管腺癌病理分化程度的价值[J]. 临床放射学杂志, 2023, 42( 11): 1768- 1773. DOI: 10.13437/j.cnki.jcr.2023.11.015.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (44) PDF downloads(14) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return